UA70287C2 - Vaccine against pleuropneomonia of pigs, method fovaccine against pleuropneomonia of pigs, method for its preparation, and method for immunizing pigs r its preparation, and method for immunizing pigs against pleuropneomonia against pleuropneomonia - Google Patents

Vaccine against pleuropneomonia of pigs, method fovaccine against pleuropneomonia of pigs, method for its preparation, and method for immunizing pigs r its preparation, and method for immunizing pigs against pleuropneomonia against pleuropneomonia Download PDF

Info

Publication number: UA70287C2
Authority: UA; Ukraine
Prior art keywords: pigs; fragment; dna; vaccine; pleuropneomonia
Prior art date: 1996-06-27

Application number

UA98126639A

Other languages

English (en)

Ukrainian (uk)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-27

Filing date

1997-06-17

Publication date

2004-10-15

1997-06-17 Application filed filed Critical

2004-10-15 Publication of UA70287C2 publication Critical patent/UA70287C2/uk

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 33
238000000034 method Methods 0.000 title claims abstract description 32
241000282887 Suidae Species 0.000 title claims abstract description 27
230000003053 immunization Effects 0.000 title claims abstract description 7
238000002360 preparation method Methods 0.000 title abstract description 7
239000002775 capsule Substances 0.000 claims abstract description 31
230000015572 biosynthetic process Effects 0.000 claims abstract description 24
238000002649 immunization Methods 0.000 claims abstract description 4
239000012634 fragment Substances 0.000 claims description 64
108090000623 proteins and genes Proteins 0.000 claims description 49
150000004676 glycans Chemical class 0.000 claims description 41
239000005017 polysaccharide Substances 0.000 claims description 41
229920001282 polysaccharide Polymers 0.000 claims description 40
241000894006 Bacteria Species 0.000 claims description 21
239000002158 endotoxin Substances 0.000 claims description 13
238000009396 hybridization Methods 0.000 claims description 10
241000204031 Mycoplasma Species 0.000 claims description 9
206010035664 Pneumonia Diseases 0.000 claims description 9
238000012217 deletion Methods 0.000 claims description 9
230000037430 deletion Effects 0.000 claims description 9
201000006509 pleuropneumonia Diseases 0.000 claims description 9
108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
244000005700 microbiome Species 0.000 claims description 8
238000011144 upstream manufacturing Methods 0.000 claims description 4
239000000304 virulence factor Substances 0.000 claims description 4
230000007923 virulence factor Effects 0.000 claims description 4
239000002095 exotoxin Substances 0.000 claims description 3
231100000776 exotoxin Toxicity 0.000 claims description 3
108090000765 processed proteins & peptides Proteins 0.000 claims description 3
230000006806 disease prevention Effects 0.000 claims description 2
230000002163 immunogen Effects 0.000 claims description 2
238000012876 topography Methods 0.000 claims 1
241000606748 Actinobacillus pleuropneumoniae Species 0.000 abstract 1
108020004414 DNA Proteins 0.000 description 78
102000053602 DNA Human genes 0.000 description 78
229930027917 kanamycin Natural products 0.000 description 19
229960000318 kanamycin Drugs 0.000 description 19
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 19
229930182823 kanamycin A Natural products 0.000 description 19
239000000523 sample Substances 0.000 description 19
108700026244 Open Reading Frames Proteins 0.000 description 18
239000002773 nucleotide Substances 0.000 description 17
125000003729 nucleotide group Chemical group 0.000 description 17
230000029142 excretion Effects 0.000 description 15
239000012528 membrane Substances 0.000 description 15
239000013612 plasmid Substances 0.000 description 15
210000004072 lung Anatomy 0.000 description 14
239000013598 vector Substances 0.000 description 14
238000002105 Southern blotting Methods 0.000 description 12
201000010099 disease Diseases 0.000 description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
102000004169 proteins and genes Human genes 0.000 description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
229920006008 lipopolysaccharide Polymers 0.000 description 11
239000003550 marker Substances 0.000 description 11
210000002966 serum Anatomy 0.000 description 11
108700012359 toxins Proteins 0.000 description 11
210000004027 cell Anatomy 0.000 description 10
239000003053 toxin Substances 0.000 description 10
231100000765 toxin Toxicity 0.000 description 10
230000001018 virulence Effects 0.000 description 10
230000001580 bacterial effect Effects 0.000 description 9
230000001332 colony forming effect Effects 0.000 description 9
238000004520 electroporation Methods 0.000 description 9
238000004458 analytical method Methods 0.000 description 8
238000003786 synthesis reaction Methods 0.000 description 8
235000010469 Glycine max Nutrition 0.000 description 7
229930006000 Sucrose Natural products 0.000 description 7
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
238000011888 autopsy Methods 0.000 description 7
210000000349 chromosome Anatomy 0.000 description 7
238000005538 encapsulation Methods 0.000 description 7
238000003119 immunoblot Methods 0.000 description 7
208000015181 infectious disease Diseases 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
239000000203 mixture Substances 0.000 description 7
239000005720 sucrose Substances 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
244000309466 calf Species 0.000 description 6
239000000499 gel Substances 0.000 description 6
230000006798 recombination Effects 0.000 description 6
238000005215 recombination Methods 0.000 description 6
108020004705 Codon Proteins 0.000 description 5
244000068988 Glycine max Species 0.000 description 5
BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 5
150000001413 amino acids Chemical group 0.000 description 5
230000002238 attenuated effect Effects 0.000 description 5
239000000872 buffer Substances 0.000 description 5
238000001962 electrophoresis Methods 0.000 description 5
239000011521 glass Substances 0.000 description 5
230000012010 growth Effects 0.000 description 5
239000004816 latex Substances 0.000 description 5
229920000126 latex Polymers 0.000 description 5
230000035945 sensitivity Effects 0.000 description 5
238000012360 testing method Methods 0.000 description 5
230000035899 viability Effects 0.000 description 5
SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 4
241000233866 Fungi Species 0.000 description 4
241001246312 Otis Species 0.000 description 4
241000282898 Sus scrofa Species 0.000 description 4
239000011543 agarose gel Substances 0.000 description 4
230000000844 anti-bacterial effect Effects 0.000 description 4
239000000427 antigen Substances 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
238000010367 cloning Methods 0.000 description 4
230000034994 death Effects 0.000 description 4
QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 4
SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
230000007062 hydrolysis Effects 0.000 description 4
238000006460 hydrolysis reaction Methods 0.000 description 4
230000000977 initiatory effect Effects 0.000 description 4
230000003902 lesion Effects 0.000 description 4
229950006238 nadide Drugs 0.000 description 4
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 3
208000000474 Poliomyelitis Diseases 0.000 description 3
241000549435 Pria Species 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
108091081024 Start codon Proteins 0.000 description 3
108020005038 Terminator Codon Proteins 0.000 description 3
239000011324 bead Substances 0.000 description 3
230000027455 binding Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000010353 genetic engineering Methods 0.000 description 3
230000028993 immune response Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
230000035772 mutation Effects 0.000 description 3
244000052769 pathogen Species 0.000 description 3
230000001717 pathogenic effect Effects 0.000 description 3
239000001509 sodium citrate Substances 0.000 description 3
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
208000030507 AIDS Diseases 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
241000283707 Capra Species 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
102000012410 DNA Ligases Human genes 0.000 description 2
108010061982 DNA Ligases Proteins 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
206010020565 Hyperaemia Diseases 0.000 description 2
208000004852 Lung Injury Diseases 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
101100150295 Mus musculus Scarf1 gene Proteins 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
101100433169 Rattus norvegicus Zdhhc2 gene Proteins 0.000 description 2
229910021607 Silver chloride Inorganic materials 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
108010008038 Synthetic Vaccines Proteins 0.000 description 2
206010069363 Traumatic lung injury Diseases 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000008272 agar Substances 0.000 description 2
230000004520 agglutination Effects 0.000 description 2
235000011114 ammonium hydroxide Nutrition 0.000 description 2
230000003698 anagen phase Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
229940041514 candida albicans extract Drugs 0.000 description 2
210000000234 capsid Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000004590 computer program Methods 0.000 description 2
238000007596 consolidation process Methods 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
231100000225 lethality Toxicity 0.000 description 2
231100000516 lung damage Toxicity 0.000 description 2
231100000515 lung injury Toxicity 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
208000008423 pleurisy Diseases 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
229940124551 recombinant vaccine Drugs 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000013518 transcription Methods 0.000 description 2
238000012065 two one-sided test Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000012138 yeast extract Substances 0.000 description 2
LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
241000501754 Astronotus ocellatus Species 0.000 description 1
244000075850 Avena orientalis Species 0.000 description 1
235000007319 Avena orientalis Nutrition 0.000 description 1
101100268269 Bacillus subtilis (strain 168) zosA gene Proteins 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
108091028026 C-DNA Proteins 0.000 description 1
108010023798 Charybdotoxin Proteins 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
238000007400 DNA extraction Methods 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
101100495315 Dictyostelium discoideum cdk5 gene Proteins 0.000 description 1
101100369915 Drosophila melanogaster stas gene Proteins 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
244000182691 Echinochloa frumentacea Species 0.000 description 1
235000008247 Echinochloa frumentacea Nutrition 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
206010015548 Euthanasia Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108700023372 Glycosyltransferases Proteins 0.000 description 1
101001018259 Homo sapiens Microtubule-associated serine/threonine-protein kinase 1 Proteins 0.000 description 1
101000693728 Homo sapiens S-acyl fatty acid synthase thioesterase, medium chain Proteins 0.000 description 1
241001026509 Kata Species 0.000 description 1
102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 1
238000011887 Necropsy Methods 0.000 description 1
101800001776 Nuclear inclusion protein B Proteins 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108091081548 Palindromic sequence Proteins 0.000 description 1
240000005546 Piper methysticum Species 0.000 description 1
235000016787 Piper methysticum Nutrition 0.000 description 1
229940124867 Poliovirus vaccine Drugs 0.000 description 1
229920001231 Polysaccharide peptide Polymers 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
101800004937 Protein C Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
102100025541 S-acyl fatty acid synthase thioesterase, medium chain Human genes 0.000 description 1
101800001700 Saposin-D Proteins 0.000 description 1
102400000827 Saposin-D Human genes 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
229940122605 Short-acting muscarinic antagonist Drugs 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
101100366647 Synechococcus elongatus (strain PCC 7942 / FACHB-805) srpH gene Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
241000700605 Viruses Species 0.000 description 1
101100006194 Yersinia enterocolitica groEL gene Proteins 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
101150108895 addB gene Proteins 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940031567 attenuated vaccine Drugs 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000009402 cross-breeding Methods 0.000 description 1
CNVQLPPZGABUCM-LIGYZCPXSA-N ctx toxin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]3CSSC[C@@H](C(N[C@@H](CC=4C5=CC=CC=C5NC=4)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CO)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3NC=NC=3)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N2)C(C)C)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC1=O)=O)CCSC)C(C)C)[C@@H](C)O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 CNVQLPPZGABUCM-LIGYZCPXSA-N 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
238000011049 filling Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
235000003869 genetically modified organism Nutrition 0.000 description 1
102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
230000036541 health Effects 0.000 description 1
244000144980 herd Species 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
238000002169 hydrotherapy Methods 0.000 description 1
230000000521 hyperimmunizing effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
229940029583 inactivated polio vaccine Drugs 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
238000004853 microextraction Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000013642 negative control Substances 0.000 description 1
229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
230000001937 non-anti-biotic effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
229960005030 other vaccine in atc Drugs 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
KSSNXJHPEFVKHY-UHFFFAOYSA-N phenol;hydrate Chemical compound O.OC1=CC=CC=C1 KSSNXJHPEFVKHY-UHFFFAOYSA-N 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
108010022457 polysaccharide peptide Proteins 0.000 description 1
235000015277 pork Nutrition 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000013615 primer Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
229960000856 protein c Drugs 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
101150080454 rexB gene Proteins 0.000 description 1
230000036280 sedation Effects 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000009331 sowing Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
101150079877 sreA gene Proteins 0.000 description 1
101150095506 srp gene Proteins 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
231100000033 toxigenic Toxicity 0.000 description 1
230000001551 toxigenic effect Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000003656 tris buffered saline Substances 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
230000000007 visual effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/825—Bacterial vaccine for porcine species, e.g. swine

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Mycology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)

UA98126639A 1996-06-27 1997-06-17 Vaccine against pleuropneomonia of pigs, method fovaccine against pleuropneomonia of pigs, method for its preparation, and method for immunizing pigs r its preparation, and method for immunizing pigs against pleuropneomonia against pleuropneomonia UA70287C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/673,814 US6086894A (en)	1996-06-27	1996-06-27	Recombinant vaccine for diseases caused by encapsulated organisms
PCT/US1997/010236 WO1997049416A1 (en)	1996-06-27	1997-06-17	Recombinant vaccine for diseases caused by encapsulated organisms

Publications (1)

Publication Number	Publication Date
UA70287C2 true UA70287C2 (en)	2004-10-15

Family

ID=24704213

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA98126639A UA70287C2 (en)	1996-06-27	1997-06-17	Vaccine against pleuropneomonia of pigs, method fovaccine against pleuropneomonia of pigs, method for its preparation, and method for immunizing pigs r its preparation, and method for immunizing pigs against pleuropneomonia against pleuropneomonia

Country Status (18)

Country	Link
US (2)	US6086894A (pl)
EP (1)	EP0964689A4 (pl)
JP (1)	JP2001522347A (pl)
CN (1)	CN1092069C (pl)
AR (1)	AR008615A1 (pl)
AU (1)	AU734254B2 (pl)
BR (1)	BR9710986A (pl)
CA (1)	CA2258168A1 (pl)
CZ (1)	CZ295438B6 (pl)
NO (1)	NO986099L (pl)
NZ (1)	NZ333387A (pl)
PL (1)	PL186728B1 (pl)
RU (1)	RU2234941C2 (pl)
SK (1)	SK284610B6 (pl)
TR (1)	TR199802716T2 (pl)
UA (1)	UA70287C2 (pl)
WO (1)	WO1997049416A1 (pl)
ZA (1)	ZA975586B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2326821C (en) *	1998-04-02	2010-09-28	The Board Of Regents Of The University Of Oklahoma	Nucleic acid encoding hyaluronan synthase and methods of use
US7708642B2 (en)	2001-10-15	2010-05-04	Igt	Gaming device having pitch-shifted sound and music
EP1914239B1 (en) *	2002-04-05	2010-06-09	Merial	Attentuated gram negative bacteria
US7449178B2 (en)	2002-04-05	2008-11-11	Merial Limited	Attenuated gram negative bacteria
GB0228691D0 (en) *	2002-12-09	2003-01-15	Imp College Innovations Ltd	Bacterial virulence genes
DE602004003582T2 (de) *	2003-07-02	2007-09-20	Biotechnology Research And Development Corp., Peoria	Akapsuläre i p. multocida hyae deletionsmutanten
JP5808671B2 (ja) *	2008-11-10	2015-11-10	ノヴォノルディスクアー／エス	機能グループｉｉ莢膜遺伝子クラスターを有しないｅ．ｃｏｌｉｂｌ２１株
TWI548746B (zh) *	2009-08-06	2016-09-11	英特威特國際股份有限公司	防備豬胸膜肺炎之疫苗及製備該疫苗之方法
CN106866800B (zh) *	2016-09-14	2020-08-18	四川农业大学	胸膜肺炎放线杆菌的体内诱导抗原及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US549818A (en) *		1895-11-12		Rolling-mill
AR241545A1 (es) *	1985-07-12	1992-08-31	Cornell Res Foundation Inc	Un metodo para preparar una cepa de s. equi avirulenta a.t.c.c. 53186 para equinos.
US4980163A (en) *	1989-03-01	1990-12-25	Public Health Research Institute Of The City Of New York	Novel bacteriocin compositions for use as enhanced broad range bactericides and methods of preventing and treating microbial infection
WO1993010815A1 (en) *	1991-12-06	1993-06-10	Center For Innovated Technology	Non-capsulated mutants of bacteria useful as vaccines
JP2717481B2 (ja) *	1992-08-25	1998-02-18	富士写真フイルム株式会社	ハロゲン化銀カラー写真感光材料
US5441736A (en) *	1992-11-05	1995-08-15	University Of Saskatchewan	Actinobacillus pleuropneumoniae outer membrane lipoprotein A and uses thereof

1996
- 1996-06-27 US US08/673,814 patent/US6086894A/en not_active Expired - Fee Related
1997
- 1997-06-17 CA CA002258168A patent/CA2258168A1/en not_active Abandoned
- 1997-06-17 EP EP97929967A patent/EP0964689A4/en not_active Withdrawn
- 1997-06-17 NZ NZ333387A patent/NZ333387A/en unknown
- 1997-06-17 PL PL97330863A patent/PL186728B1/pl not_active IP Right Cessation
- 1997-06-17 JP JP50314698A patent/JP2001522347A/ja not_active Ceased
- 1997-06-17 RU RU99101907/13A patent/RU2234941C2/ru not_active IP Right Cessation
- 1997-06-17 UA UA98126639A patent/UA70287C2/uk unknown
- 1997-06-17 AU AU33904/97A patent/AU734254B2/en not_active Ceased
- 1997-06-17 CN CN97195844A patent/CN1092069C/zh not_active Expired - Fee Related
- 1997-06-17 WO PCT/US1997/010236 patent/WO1997049416A1/en not_active Ceased
- 1997-06-17 TR TR1998/02716T patent/TR199802716T2/xx unknown
- 1997-06-17 CZ CZ19984189A patent/CZ295438B6/cs not_active IP Right Cessation
- 1997-06-17 BR BR9710986-0A patent/BR9710986A/pt active Search and Examination
- 1997-06-17 SK SK1771-98A patent/SK284610B6/sk unknown
- 1997-06-24 ZA ZA9705586A patent/ZA975586B/xx unknown
- 1997-06-24 AR ARP970102777A patent/AR008615A1/es unknown
1998
- 1998-07-15 US US09/115,824 patent/US6326001B1/en not_active Expired - Fee Related
- 1998-12-23 NO NO986099A patent/NO986099L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NZ333387A (en)	2000-06-23
NO986099L (no)	1999-01-13
PL330863A1 (en)	1999-06-07
SK284610B6 (sk)	2005-07-01
CN1092069C (zh)	2002-10-09
JP2001522347A (ja)	2001-11-13
AU734254B2 (en)	2001-06-07
RU2234941C2 (ru)	2004-08-27
PL186728B1 (pl)	2004-02-27
CZ295438B6 (cs)	2005-08-17
BR9710986A (pt)	2001-12-11
EP0964689A4 (en)	2004-09-08
AU3390497A (en)	1998-01-14
CZ418998A3 (cs)	1999-07-14
CN1223586A (zh)	1999-07-21
HK1020004A1 (en)	2000-03-10
EP0964689A1 (en)	1999-12-22
SK177198A3 (en)	2000-03-13
NO986099D0 (no)	1998-12-23
US6326001B1 (en)	2001-12-04
ZA975586B (en)	1998-03-23
WO1997049416A1 (en)	1997-12-31
TR199802716T2 (xx)	2001-06-21
US6086894A (en)	2000-07-11
CA2258168A1 (en)	1997-12-31
AR008615A1 (es)	2000-02-09

Publication	Publication Date	Title
US20260137772A1 (en)	2026-05-21	Variant strain-based coronavirus vaccines
US8846057B2 (en)	2014-09-30	Recombinant live attenuated foot-and-mouth disease (FMD) vaccine containing mutations in the L protein coding region
Wang et al.	2021	Establishment of full-length cDNA clones and an efficient oral infection model for feline coronavirus in cats
JP3602759B2 (ja)	2004-12-15	弱毒型のウシウィルス性下痢性ウィルス
EP4188941A2 (en)	2023-06-07	Modified chikungunya viruses and sindbis viruses and uses thereof
JP4632540B2 (ja)	2011-02-16	弱毒化ペスチウイルス
CN119698293A (zh)	2025-03-25	重组猪冠状病毒
RU2234941C2 (ru)	2004-08-27	Вакцина против плевропневмонии животных, способ ее получения
JP2024500225A (ja)	2024-01-05	安定細胞株において効率的な増殖を可能にする、アフリカ豚熱ワクチンにおけるゲノム欠失
US12453767B2 (en)	2025-10-28	Development of mosaic vaccines against foot and mouth disease virus serotype O
CN113186171B (zh)	2023-01-24	一种黄病毒属病毒的减毒病毒及其用途
EP4036226A1 (en)	2022-08-03	Attenuated african swine fever virus and its use as a vaccine
CN109735477B (zh)	2022-07-05	单核细胞增生李斯特菌三基因缺失减毒突变株制备及其应用
MXPA05012754A (es)	2006-05-17	Vacunas virales atenuadas vivas para virus de encefalitis equina oriental.
US7541447B2 (en)	2009-06-02	Process for the preparation of an improved Brucella strain plasmid to develop the strain and the vaccine comprising the said strain
WO2011077143A1 (en)	2011-06-30	Transformation of commensal neisseria
CN109337874B (zh)	2020-05-12	一种重组猪伪狂犬病毒及其应用和重组猪伪狂犬病活疫苗
Hosamani et al.	2008	Cell culture adapted sheeppox virus as a challenge virus for potency testing of sheeppox vaccine
KR100567351B1 (ko)	2007-05-14	피낭형세균에의해유발되는질병에대한재조합백신
Dehan et al.	2005	Point mutations in an infectious bovine viral diarrhoea virus type 2 cDNA transcript that yields an attenuated and protective viral progeny
WO2025129186A1 (en)	2025-06-19	Clostridioides difficile vaccine and methods of use
KR20240175353A (ko)	2024-12-20	일본 뇌염 바이러스 유전형 5 국내 분리주 mk541529.1에 대한 재조합 바이러스 및 이의 용도
EA052121B1 (ru)	2026-01-14	Композиции и способы профилактики и лечения инфекции, вызванной вирусом бешенства
CN116867518A (zh)	2023-10-10	包含表达SARS-CoV-2蛋白质的一种或多种修饰的BCG菌株的免疫原性制剂，用于预防、治疗或减弱COVID-19的发展
HK1020004B (en)	2003-06-20	Recombinant vaccine for diseases caused by encapsulated organisms